Top Markets
Coin of the day
CytoMed Therapeutics Limited CytoMed Therapeutics Limited

CytoMed Therapeutics Limited

GDTC
Kedudukan dalam Saham #32327
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical... CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
Harga Saham
$0.88
Disegerakkan terakhir: 2026-08-17
Modal Pasaran
$10.41M
Perubahan (1 hari)
-7.26%
Perubahan (1 tahun)
-50.56%
Negara
SG
Perdagangan CytoMed Therapeutics Limited (GDTC)

Kategori

Nisbah P/B bagi CytoMed Therapeutics Limited (GDTC)
Nisbah P/B pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini CytoMed Therapeutics Limited, nisbah P/B semasa (TTM) ialah 0. Pada akhir 2026, nisbah P/B syarikat ialah 0.
Sejarah nisbah P/B untuk CytoMed Therapeutics Limited dari 2026 hingga 2026
Nisbah P/B pada akhir setiap tahun
Tahun Nisbah P/B Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/B untuk syarikat atau pesaing yang serupa
Syarikat Nisbah P/B Perbezaan Nisbah P/B Negara
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH
3.4612 -
BE